Adverse events following pandemic influenza vaccine Pandemrix® reported in the French military forces-2009-2010

被引:32
|
作者
Mayet, Aurelie [1 ]
Ligier, Caroline [1 ]
Gache, Kristel [1 ]
Manet, Ghislain [1 ]
Nivoix, Philippe [2 ]
Dia, Aissata [2 ]
Haus-Cheymol, Rachel [1 ]
Verret, Catherine [1 ]
Duron, Sandrine [1 ]
Faure, Nina [2 ]
Piarroux, Martine [2 ]
De Laval, Frank [2 ]
Simon, Fabrice [3 ]
Decam, Christophe [2 ]
Chaudet, Herve [2 ]
Meynard, Jean-Baptiste [1 ]
Rapp, Christophe [4 ]
Deparis, Xavier [2 ]
Migliani, Rene [1 ]
机构
[1] Ecole Val de Grace, Dept Epidemiol & Sante Publ Nord, Paris, France
[2] Inst Med Trop Serv Sante Armees, Dept Epidemiol & Sante Publ Sud, Marseille, France
[3] Hop Instruct Armees Laveran, Serv Pathol Infect & Trop, Marseille, France
[4] Hop Instruct Armees Begin, Serv Pathol Infect & Trop, St Mande, France
关键词
Influenza; Military forces; Pandemic; Vaccine; Vaccine adverse event; GUILLAIN-BARRE-SYNDROME; A VIRUS;
D O I
10.1016/j.vaccine.2011.01.056
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: In the face of the A(H1N1) 2009 influenza pandemic, in October 2009 the French military health service (SSA) initiated a large vaccination campaign with Pandemrix (R) vaccine in the military forces. The aim of this study was to describe vaccine adverse events (VAE) reported during this campaign. Methods: VAE and the number of people vaccinated were surveyed by the SSA Epidemiological network across all military forces during the campaign, from October 2009 to April 2010. For each case, a notification form was completed, providing patient and clinical information. Three types of VAE were considered: non-serious, serious and unexpected. Results: There were 315.4 reported VAE per 100,000 vaccinations. Vaccination and VAE incidence rate peaks coincided with influenza epidemic peak in early December. The number of injected doses was 49,138, corresponding to a 14.5% vaccination coverage among military personnel, and 155 VAE were reported, including 5 serious VAE (1 Guillain-Barre syndrome, 2 malaises and 1 convulsive episode). Most VAE were non-serious (97.1%). Among these, 6 cases of local, rapidly regressive paresthesia were observed. Discussion: The military VAE surveillance system constitutes the only observatory on benign VAE in France. The reporting rate was much higher after the pandemic vaccine than after the seasonal vaccine, which may be a reflection of stimulated reporting. This report provides a useful description of VAE among military personnel during a mass emergency vaccination program, showing that the tolerance of the pandemic vaccine appeared acceptable. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2576 / 2581
页数:6
相关论文
共 50 条
  • [41] Risk of presentation to hospital with epileptic seizures after vaccination with monovalent AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine (Pandemrix): self controlled case series study
    Arnheim-Dahlstrom, Lisen
    Hallgren, Jonas
    Weibull, Caroline E.
    Sparen, Par
    BMJ-BRITISH MEDICAL JOURNAL, 2012, 345
  • [42] Comparison of adverse events following immunization with pandemic influenza A (H1N1)pdm09 vaccine with or without adjuvant among health professionals in Rio de Janeiro, Brazil
    Cerbino-Neto, Jose
    da Silva Santos, Ananza Taina
    Fragoso da Silveira Gouvea, Maria Isabel
    Pedro, Renata Saraiva
    Ramos, Grazielle Viana
    Guaraldo, Lusiele
    Werneck, Guilherme Loureiro
    MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2012, 107 (07): : 923 - 927
  • [43] Factors Associated With Uptake of the Influenza A(H1N1)pdm09 Monovalent Pandemic Vaccine in K-12 Public Schools, Maine 2009-2010
    Lorick, Suchita A.
    Goldberg, Lisa
    Zhang, Fan
    Birkhimer, Nancy
    Dube, Nancy
    Dutram, Kay
    Hubley, Teresa
    Tipton, Meredith
    Basurto-Davila, Ricardo
    Graitcer, Sam
    Mills, Dora Anne
    JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE, 2015, 21 (02) : 186 - 195
  • [44] Are Kenyan healthcare workers willing to receive the pandemic influenza vaccine? Results from a cross-sectional survey of healthcare workers in Kenya about knowledge, attitudes and practices concerning infection with and vaccination against 2009 pandemic influenza A (H1N1), 2010
    Oria, Prisca A.
    Matini, Wycliffe
    Nelligan, Ian
    Emukule, Gideon
    Scherzer, Martha
    Oyier, Beryl
    Ochieng, Hezron N.
    Hooper, Laura
    Kanyuga, Anne
    Muthoka, Phillip
    Morales, Kathleen F.
    Nzioka, Charles
    Breiman, Robert F.
    Katz, Mark A.
    VACCINE, 2011, 29 (19) : 3617 - 3622
  • [45] Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older
    Ikematsu, Hideyuki
    Tenjinbaru, Kazuyoshi
    Li, Ping
    Madan, Anuradha
    Vaughn, David
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (08) : 1119 - 1125
  • [46] Cholera and COVID-19 pandemic prevention in multiple hotspot districts of Uganda: vaccine coverage, adverse events following immunization and WASH conditions survey
    Godfrey Bwire
    Annet Kisakye
    Esther Amulen
    John Baptist Bwanika
    Joan Badebye
    Christine Aanyu
    Brenda Doreen Nakirya
    Alfred Okello
    Stephen Acellam Okello
    Justine N. Bukenya
    Christopher Garimoi Orach
    BMC Infectious Diseases, 23
  • [47] Cholera and COVID-19 pandemic prevention in multiple hotspot districts of Uganda: vaccine coverage, adverse events following immunization and WASH conditions survey
    Bwire, Godfrey
    Kisakye, Annet
    Amulen, Esther
    Bwanika, John Baptist
    Badebye, Joan
    Aanyu, Christine
    Nakirya, Brenda Doreen
    Okello, Alfred
    Okello, Stephen Acellam
    Bukenya, Justine N.
    Orach, Christopher Garimoi
    BMC INFECTIOUS DISEASES, 2023, 23 (01)
  • [48] Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with Type 1 diabetes mellitus
    Zuccotti, G. V.
    Pariani, E.
    Scaramuzza, A.
    Santoro, L.
    Giani, E.
    Macedoni, M.
    Gazzarri, A.
    Anselmi, G.
    Amendola, A.
    Zanetti, A.
    DIABETIC MEDICINE, 2011, 28 (12) : 1530 - 1536
  • [49] Patterns in influenza antiviral medication use before and during the 2009 H1N1 pandemic, Vaccine Safety Datalink Project, 2000-2010
    Greene, Sharon K.
    Shay, David K.
    Yin, Ruihua
    McCarthy, Natalie L.
    Baxter, Roger
    Jackson, Michael L.
    Jacobsen, Steven J.
    Nordin, James D.
    Irving, Stephanie A.
    Naleway, Allison L.
    Glanz, Jason M.
    Lieu, Tracy A.
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2012, 6 (06) : e143 - e151
  • [50] Analysis of participant-reported adverse events following the first dose of inactivated SARS-Cov-2 vaccine (TURKOVAC™) through telephone survey in Turkiye
    Kara, Ates
    Coskun, Aslihan
    Temel, Fehminaz
    Ozelci, Pervin
    Topal, Selmur
    Ates, Ihsan
    ANNALS OF MEDICINE, 2023, 55 (01) : 1070 - 1079